上客户端，和病友交流
点击下载
返回
胃癌
Anthony Shields M.D., Ph.D.

Anthony Shields M.D., Ph.D.

外科
Karmanos cancer center

擅长疾病

临床新药咨询

通过咨询找到适合自己的药物

专家会诊咨询

专业、及时的一对一咨询

如果您的问题未能解决，您还可以选择：

医学顾问

极速问诊

2万名名医
7*24小时为您匹配
1对1

找专家

肿瘤专科专家
对症找医专科专治

专家介绍

2015-06-17 15:572716
 ·         Gender

·         Male

·         Multidisciplinary Team(s)

·         Gastrointestinal Oncology 

·         Department/Research Program(s)

·         Department of Oncology 
Molecular Imaging & Diagnostics Program 

·         Cancer Type(s)

·         Ampullary and periampullary cancers 
Anal Cancer 
Appendix Cancer 
Bile Duct Cancer 
Cancer of unknown origin 
Carcinoid Tumors 
Cholangiocarcinoma 
colon Cancer 
Esophageal Cancer 
Gall Bladder Cancer 
Gastroesophageal Junction (GEJ) 
Gastrointestinal Stromal Tumors (GIST) 
Liver Cancer 
Neuroendocrine Tumors 
Pancreatic Cancer 
Pancreatic Neuroendocrine Tumor (pNET) 
Peritoneum and psuedomyxoma peritonii 
Rectal Cancer 
Small Intestine Cancer 
Stomach Cancer 

·         Contact Info

·         Email:
shieldsa@karmanos.org

 

来自 <http://www.karmanos.org/physicians/Anthony-Shields?Disease=238&PageIndex=0&SortDirection=1>

 

·         Education

·         Fellowship
Medical oncology Fellowship: University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington
Medical School
Harvard Medical School
Residency
Internal Medicine, University of Washington School of Medicine, Seattle, Washington
Graduate Training
Massachusetts Institute of Technology (Ph.D)

·         Professional Memberships/Associations

·         American Society of Clinical Oncology 
American Society of Hematology 
Society of Nuclear Medicine 
American Association for Cancer Research 
American Society for Microbiology 
World Molecular Imaging Society 

·         Board Certifications

·         American Board of Internal Medicine
National Board of Medical Examiners
American Board of Medical oncology and Hematology

·         Clinical Interests

·         Medical Oncology, Gastrointestinal Oncology 

·         Research Interests

·         Gastrointestinal Oncology, Molecular Imaging to assess treatment response, Imaging Agents 

·         Profile

·         Dr. Shields' career has been dedicated to clinical research and the care of patients with colorectal, pancreatic and other gastrointestinal cancers. His experiences in research and the clinic make him painfully aware of the need to develop new approaches in understanding and overcoming resistance to treatment for patients with GI cancer. At Karmanos Cancer Institute and Wayne University School of Medicine he leads clinical research efforts through his roles as the Associate Center Director for Clinical Sciences, Program Leader in Molecular Imaging and Diagnostics and Professor of oncology and Medicine. Dr. Shields training as a Medical oncologist provides the insight to guide studies in patients with cancer and the foresight to design trials that are appropriate. He has a broad understanding in clinical sciences with experience that spans from protocol design and development to implementation from the local to the national level. He is the sub-chair for colorectal cancer at the Southwest oncology Group (SWOG), and co-chair for a national adjuvant colon cancer study sponsored by the Cancer and Leukemia Group B (CALGB) and SWOG. He serves on the NCI colon Task Force, which is charged with overseeing clinical research studies in colorectal cancer, and has served on the NCI Investigational Drug Steering Committee. In the clinic, his work concentrates on the treatment of patients with gastrointestinal (GI) cancer and he continues to develop and lead new clinical trials for GI tumors. This includes serving as a founding faculty member of the Clinical Trials Methodology Workshop under the sponsorships of the Radiological Society of North America (RSNA) and the National Cancer Institute, which is designed to mentor new faculty. As an Associate Center Director for Clinical Sciences, and member of the Human Investigation Committee Review Board, he helps to oversee a large number of clinical studies within our Institute and comprehends the complexities and challenges of the approaches to successful evaluation of new agents. Dr. Shields clearly has a crucial role in the design of cancer clinical trials. His laboratory research focuses on the development and testing of tracers for use with positron emission tomography (PET) for the assessment of a variety of tumors (e.g. brain, lung, breast, and prostate cancers) and their response to treatment. Dr. Shields led the development of FLT {3'-deoxy-3'-fluorothymidine}; a promising tracer for tumor proliferation, which has received an IND from the FDA and is being tested in centers worldwide. He serves on the Steering Committee of the American College of Radiology (ACRIN) and the National oncology PET Registry (NOPR) and works to incorporate innovative imaging in the multicenter clinical trials. He is Senior Editor for Molecular Imaging and Biology and the Journal of Nuclear Medicine, and a reviewer for a number of journals, including the New England Journal of Medicine, Nature Medicine, and The Journal of Clinical Oncology. He has authored over 100 peer-reviewed articles and more than 20 book chapters, reviews and case reports on cancer research.

·         Awards

·         2005, 2009-2013 Voted one of the Best Doctor's in America by Best Doctors Inc.
Selected by Castle Connolly Medical Ltd. as one of the region's Top Doctors
2007 Wayne State University Distinguished Faculty Fellowship Award
2005 European Association of Nuclear Medicine and Springer-Verlag Award - Best Clinical Paper
2005 Peter Valk Distinguished Clinical Scientist Award, Academy of Molecular Imaging

·         Publications

·         Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 307:1383-93. 2012. PMID: 22474202 Authors: Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM.
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs, 29:694-9, 2011. Epub Jan 27, 2010. PMID: 20107864. Authors: El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL.
Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience. Am J Clin Oncol. 34:135-9. 2011. PMID: 20523206 Authors: Hammad N, Heilbrun LK, Gupta S, Tageja N, Philip PA, Shields AF, Smith D, El-Rayes BF
Impact of dedicated brain PET on intended patient management in participants of the National oncologic PET Registry. Mol Imaging Biol. 13:161-5, 2011. Epub Oct 7, 2010. PMID: 2108023 Authors: Hillner BE, Siegel BA, Shields AF, Fenghai D, Gareen IF, Hanna L, Coleman RE.
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Invest New Drugs. 29: 1395-405, 2011. Epub Jul 6, 2010. PMID: 20607586 Authors: Lorusso P, Shields AF, Gadgeel S, Vaishampayan U, Guthrie T, Puchalski T, Xu J, Liu Q.

 

来自 <http://www.karmanos.org/Physicians/Details.aspx?sid=1&physician=35&Disease=238&PageIndex=0&SortDirection=1>

 

 

 

 

 

1. 添加医学顾问微信，扫描☟二维码

2. 备注【癌种】进病友群

扫描预约专家问诊

专家科普

同类全球会诊
合作伙伴：